Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld; David M. Brown; Jeffrey S. Heier; David S. Boyer; Peter K. Kaiser; Carol Chung; Robert Y. Kim

doi:10.1056/nejmoa054481

Abstract

Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. (ClinicalTrials.gov number, NCT00056836 [ClinicalTrials.gov].).

Keywords

Macular degenerationRanibizumabMedicineMonoclonalOphthalmologyVascular endothelial growth factorMonoclonal antibodyBevacizumabDegeneration (medical)Recombinant DNAVEGF receptorsAntibodySurgeryInternal medicineImmunologyChemotherapy

MeSH Terms

AgedAged80 and overAngiogenesis InhibitorsAntibodiesMonoclonalAntibodiesMonoclonalHumanizedChoroidal NeovascularizationDouble-Blind MethodFemaleHumansInjectionsMacular DegenerationMaleMiddle AgedOptic DiskRanibizumabVisual Acuity

Affiliated Institutions

Related Publications

Age-related macular degeneration

Paul Mitchell , Gerald Liew , Bamini Gopinath +1 more

Age-related macular degeneration is a leading cause of visual impairment and severe vision loss. Clinically, it is classified as early-stage (medium-sized drusen and retinal pig...

2018 The Lancet 1438 citations

Photodynamic therapy for circumscribed choroidal haemangioma

Irène Landau , Björn Steén , Stefan Seregard

ABSTRACT. Purpose: To assess the efficacy of photodynamic therapy (PDT) as a new treatment for circumscribed choroidal haemangioma (CCH). Methods: Eight patients with CCH were t...

2002 Acta Ophthalmologica Scandinavica 57 citations

Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study

Reza Dana , Lalit Dandona , Rakhi Dandona +97 more

Many causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence a...

2020 The Lancet Global Health 2687 citations

Construction and Delivery of Tissue-Engineered Human Retinal Pigment Epithelial Cell Sheets, Using Magnetite Nanoparticles and Magnetic Force

Akira Itô , Eri Hibino , Chiaki Kobayashi +5 more

Choroidal neovascularization (CNV) is the most severe form of age-related macular degeneration (AMD), which causes rapid visual loss. Transplantation of cultured retinal pigment...

2005 Tissue Engineering 137 citations

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model

Richard S. Finn , Greg Bentley , Carolyn D. Britten +2 more

Abstract Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Liver resection or transplantation is curative for a subset o...

2009 Liver International 73 citations

Publication Info

Year: 2006
Type: article
Volume: 355
Issue: 14
Pages: 1419-1431
Citations: 5737
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Ranibizumab for Neovascular Age-Related Macular Degeneration

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5737

OpenAlex

Influential

4417

CrossRef

Cite This

APA Style

                            
                                
                                    Philip J. Rosenfeld, 
                                
                                    David M. Brown, 
                                
                                    Jeffrey S. Heier
                                
                                et al.
                            
                            (2006). 
                            Ranibizumab for Neovascular Age-Related Macular Degeneration. 
                            New England Journal of Medicine
                            , 355
                            (14)
                            , 1419-1431.
                            https://doi.org/10.1056/nejmoa054481
                        

Identifiers

DOI: 10.1056/nejmoa054481
PMID: 17021318

Data Quality

Data completeness: 86%